{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:37:51Z","timestamp":1780735071706,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with secondary adrenal insufficiency (SAI) have an increased morbidity and an impaired health-related quality of life (HRQoL), which seems to primarily depend on the sub-optimal replacement of hypoadrenalism with standard glucocorticoid (GC) therapy, and on the inadequate correction of other associated pituitary deficiencies. A dual-release hydrocortisone (DR-HC) formulation has shown to exert positive effects on morbidity and HRQoL, mainly in patients with primary adrenal insufficiency. We assessed the variations of anthropometric and metabolic parameters and HRQoL in patients with SAI after switching from cortisone acetate (CA) or hydrocortisone (HC) to DR-HC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-one patients (17\u00a0M, 4 F) treated with CA (<jats:italic>n<\/jats:italic>\u2009=\u200916; 25\u00a0mg\/day twice a day) or HC (<jats:italic>n<\/jats:italic>\u2009=\u20095; 20\u00a0mg\/day three times a day), were evaluated for waist circumference, BMI, fasting glucose, HbA1c, insulin, HOMA-IR index, serum lipids, electrolytes, blood pressure and HRQoL at baseline, at 3, 6 and 12\u00a0months after switching from CA\/HC to DR-HC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study showed a significant reduction of waist circumference and BMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.04, for both), after 3 and 6months of DR-HC treatment, respectively. No significant changes were observed for fasting glucose, insulin, HOMA-IR index, HbA1c, total cholesterol, triglycerides, LDL cholesterol, electrolytes, and blood pressure. However, HDL cholesterol significantly decreased (<jats:italic>p<\/jats:italic>\u2009=\u20090.003). An improvement of AddiQoL total score was observed during DR-HC treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.01), mainly for the category \u201cemotions\u201d. No predictors resulted for these changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DR-HC treatment provides some benefits in patients with SAI, reducing central adiposity and improving HRQoL; however, worsening of HDL cholesterol is observed during treatment with DR-HC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01940-1","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:04:00Z","timestamp":1666004640000},"page":"587-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency"],"prefix":"10.1007","volume":"46","author":[{"given":"V.","family":"Gasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Campioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Arvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maccario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-3532","authenticated-orcid":false,"given":"R.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1210\/jc.2010-0982","volume":"95","author":"AB Grossman","year":"2010","unstructured":"Grossman AB (2010) The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 95:4855\u20134863. https:\/\/doi.org\/10.1210\/jc.2010-0982","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR2","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1210\/jc.2014-2476","volume":"99","author":"RK Crowley","year":"2014","unstructured":"Crowley RK, Argese N, Tomlinson JW, Stewart PM (2014) Central hypoadrenalism. J Clin Endocrinol Metab 99:4027\u20134036. https:\/\/doi.org\/10.1210\/jc.2014-2476","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2006-0524","volume":"91","author":"H Filipsson","year":"2006","unstructured":"Filipsson H, Monson JP, Koltowska-H\u00e4ggstr\u00f6m M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954\u20133961. https:\/\/doi.org\/10.1210\/jc.2006-0524","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-17-0340","volume":"177","author":"C Hammarstrand","year":"2017","unstructured":"Hammarstrand C, Ragnarsson O, Hall\u00e9n T, Andersson E, Skoglund T, Nilsson AG, Johannsson G, Olsson DS (2017) Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol 177:251\u2013256. https:\/\/doi.org\/10.1530\/EJE-17-0340","journal-title":"Eur J Endocrinol"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1530\/EJE-09-0170","volume":"161","author":"G Johannsson","year":"2009","unstructured":"Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S (2009) Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161:119\u2013130. https:\/\/doi.org\/10.1530\/EJE-09-0170","journal-title":"Eur J Endocrinol"},{"key":"1940_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","volume":"97","author":"G Johannsson","year":"2012","unstructured":"Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstr\u00f6m BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennern\u00e4s H, Skrtic S (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473\u2013481. https:\/\/doi.org\/10.1210\/jc.2011-1926","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1530\/EJE-14-0327","volume":"171","author":"AG Nilsson","year":"2014","unstructured":"Nilsson AG, Marelli C, Fitts D, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstr\u00f6m BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Lennern\u00e4s H, Skrtic S, Johannsson G (2014) Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur J Endocrinol 171:369\u2013377. https:\/\/doi.org\/10.1530\/EJE-14-0327","journal-title":"Eur J Endocrinol"},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, \u00d8ksnes M (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619\u2013626. https:\/\/doi.org\/10.1530\/EJE-14-1114","journal-title":"Eur J Endocrinol"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","volume":"51","author":"R Giordano","year":"2016","unstructured":"Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, Lucchiari M, Manetta T, Mengozzi G, Arvat E, Ghigo E (2016) Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison\u2019s disease. Endocrine 51:360\u2013368. https:\/\/doi.org\/10.1007\/s12020-015-0681-z","journal-title":"Endocrine"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EC-19-0176","volume":"8","author":"V Guarnotta","year":"2019","unstructured":"Guarnotta V, Di Stefano C, Santoro A, Ciresi A, Coppola A, Giordano C (2019) Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr Connect 8:853\u2013862. https:\/\/doi.org\/10.1530\/EC-19-0176","journal-title":"Endocr Connect"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"204201881987116","DOI":"10.1177\/2042018819871169","volume":"10","author":"V Guarnotta","year":"2019","unstructured":"Guarnotta V, Mineo MI, Radellini S, Pizzolanti G, Giordano C (2019) Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. Ther Adv Endocrinol Metab 10:2042018819871169. https:\/\/doi.org\/10.1177\/2042018819871169","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1530\/EC-18-0257","volume":"7","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Selmin E, Sabbadin C, Dalla Costa M, Antonelli G, Plebani M, Barbot M, Betterle C, Boscaro M, Scaroni C (2018) Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr Connect 7:965\u2013974. https:\/\/doi.org\/10.1530\/EC-18-0257","journal-title":"Endocr Connect"},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","volume":"60","author":"S Frara","year":"2018","unstructured":"Frara S, Chiloiro S, Porcelli T, Giampietro A, Mazziotti G, De Marinis L, Giustina A (2018) Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60:528\u2013531. https:\/\/doi.org\/10.1007\/s12020-017-1512-1","journal-title":"Endocrine"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EC-17-0368","volume":"7","author":"LM Mongio\u00ec","year":"2018","unstructured":"Mongio\u00ec LM, Condorelli RA, La Vignera S, Calogero AE (2018) Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr Connect 7:211\u2013219. https:\/\/doi.org\/10.1530\/EC-17-0368","journal-title":"Endocr Connect"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1530\/EJE-20-0642","volume":"184","author":"R Dineen","year":"2021","unstructured":"Dineen R, Martin-Grace J, Ahmed KMS, Frizelle I, Gunness A, Garrahy A, Hannon AM, O\u2019Reilly MW, Smith D, McDermott J, Healy ML, Agha A, Pazderska A, Gibney J, Thompson CJ, Behan LA, Sherlock M (2021) Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study. Eur J Endocrinol 184:253\u2013265. https:\/\/doi.org\/10.1530\/EJE-20-0642","journal-title":"Eur J Endocrinol"},{"key":"1940_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1210\/jc.2009-1711","volume":"95","author":"K L\u00f8v\u00e5s","year":"2010","unstructured":"L\u00f8v\u00e5s K, Curran S, Oksnes M, Husebye ES, Huppert FA, Chatterjee VK (2010) Development of a disease-specific quality of life questionnaire in Addison\u2019s disease. J Clin Endocrinol Metab 95:545\u2013551. https:\/\/doi.org\/10.1210\/jc.2009-1711","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1210\/jc.2011-1901","volume":"97","author":"M \u00d8ksnes","year":"2012","unstructured":"\u00d8ksnes M, Bensing S, Hulting AL, K\u00e4mpe O, Hackemann A, Meyer G, Badenhoop K, Betterle C, Parolo A, Giordano R, Falorni A, Papierska L, Jeske W, Kasperlik-Zaluska AA, Chatterjee VK, Husebye ES, L\u00f8v\u00e5s K (2012) Quality of life in European patients with Addison\u2019s disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 97:568\u2013576. https:\/\/doi.org\/10.1210\/jc.2011-1901","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF03346389","volume":"31","author":"G Aimaretti","year":"2008","unstructured":"Aimaretti G, Boschetti M, Corneli G, Gasco V, Valle D, Borsotti M, Rossi A, Barreca A, Fazzuoli L, Ferone D, Ghigo E, Minuto F (2008) Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest 31:445\u2013449. https:\/\/doi.org\/10.1007\/BF03346389","journal-title":"J Endocrinol Invest"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2265.1995.tb02928.x","volume":"43","author":"FP Dunne","year":"1995","unstructured":"Dunne FP, Elliot P, Gammage MD, Stallard T, Ryan T, Sheppard MC, Stewart PM (1995) Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf) 43:623\u2013629. https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02928.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2265.1995.tb02602.x","volume":"42","author":"al-Shoumer KA, Beshyah SA, Niththya","year":"1995","unstructured":"al-Shoumer KA, Beshyah SA, Niththyananthan R, Johnston DG, (1995) Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol (Oxf) 42:85\u201390. https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02602.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1940_CR23","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1210\/jc.2007-0685","volume":"92","author":"S Hahner","year":"2007","unstructured":"Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W, Allolio B (2007) Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 92:3912\u20133922. https:\/\/doi.org\/10.1210\/jc.2007-0685","journal-title":"J Clin Endocrinol Metab"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1530\/EJE-08-0578","volume":"159","author":"B Bleicken","year":"2008","unstructured":"Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M (2008) Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 159:811\u2013817. https:\/\/doi.org\/10.1530\/EJE-08-0578","journal-title":"Eur J Endocrinol"},{"key":"1940_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6823-12-8","volume":"12","author":"M Forss","year":"2012","unstructured":"Forss M, Batcheller G, Skrtic S, Johannsson G (2012) Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord 12:8. https:\/\/doi.org\/10.1186\/1472-6823-12-8","journal-title":"BMC Endocr Disord"},{"key":"1940_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1530\/EJE-12-0351","volume":"167","author":"S Benson","year":"2012","unstructured":"Benson S, Neumann P, Unger N, Schedlowski M, Mann K, Elsenbruch S, Petersenn S (2012) Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol 167:679\u2013685. https:\/\/doi.org\/10.1530\/EJE-12-0351","journal-title":"Eur J Endocrinol"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1530\/EJE-14-0397","volume":"171","author":"O Ragnarsson","year":"2014","unstructured":"Ragnarsson O, Mattsson AF, Monson JP, Filipsson Nystr\u00f6m H, \u00c5kerblad AC, Ko\u0142towska-H\u00e4ggstr\u00f6m M, Johannsson G (2014) The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. Eur J Endocrinol 171:571\u2013579. https:\/\/doi.org\/10.1530\/EJE-14-0397","journal-title":"Eur J Endocrinol"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/j.1552-4604.1991.tb01906.x29","volume":"31","author":"H Derendorf","year":"1991","unstructured":"Derendorf H, M\u00f6llmann H, Barth J, M\u00f6llmann C, Tunn S, Krieg M (1991) Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 31:473\u2013476. https:\/\/doi.org\/10.1002\/j.1552-4604.1991.tb01906.x29","journal-title":"J Clin Pharmacol"},{"issue":"Suppl2","key":"1940_CR29","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1038\/sj.ijo.0801276","volume":"24","author":"MF Dallman","year":"2000","unstructured":"Dallman MF, Akana SF, Bhatnagar S, Bell ME, Strack AM (2000) Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentrations. Int J Obes Relat Metab Disord 24(Suppl2):S40\u2013S46. https:\/\/doi.org\/10.1038\/sj.ijo.0801276","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1940_CR30","first-page":"212","volume":"62","author":"W Oelkers","year":"2001","unstructured":"Oelkers W, Diederich S, B\u00e4hr V (2001) Therapeutic strategies in adrenal insufficiency. Ann Endocrinol (Paris) 62:212\u2013216","journal-title":"Ann Endocrinol (Paris)"},{"key":"1940_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/er.2015-1080","volume":"38","author":"H Oster","year":"2017","unstructured":"Oster H, Challet E, Ott V, Arvat E, de Kloet ER, Dijk DJ, Lightman S, Vgontzas A, Van Cauter E (2017) The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocr Rev 38:3\u201345. https:\/\/doi.org\/10.1210\/er.2015-1080","journal-title":"Endocr Rev"},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S, Roca E, Mortini P, Berruti A, Giustina A (2017) MANAGEMENT OF ENDOCRINE DISEASE: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177:R231\u2013R248. https:\/\/doi.org\/10.1530\/EJE-17-0154","journal-title":"Eur J Endocrinol"},{"key":"1940_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/cs0960513","volume":"96","author":"RC Andrews","year":"1999","unstructured":"Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96:513\u2013523. https:\/\/doi.org\/10.1042\/cs0960513","journal-title":"Clin Sci (Lond)"},{"issue":"Suppl 1","key":"1940_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","volume":"92","author":"G Arnaldi","year":"2010","unstructured":"Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M (2010) Pathophysiology of dyslipidemia in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):86\u201390. https:\/\/doi.org\/10.1159\/000314213","journal-title":"Neuroendocrinology"},{"key":"1940_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2265.1996.tb02057.x","volume":"45","author":"J Rodr\u00edguez-Arnao","year":"1996","unstructured":"Rodr\u00edguez-Arnao J, Perry L, Besser GM, Ross RJ (1996) Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 45:33\u201337. https:\/\/doi.org\/10.1111\/j.1365-2265.1996.tb02057.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1940_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1046\/j.1365-2265.2003.01894.x","volume":"59","author":"FM Swords","year":"2003","unstructured":"Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP (2003) The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 59:613\u2013620. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01894.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9 Suppl","key":"1940_CR37","first-page":"61","volume":"31","author":"C Scaroni","year":"2008","unstructured":"Scaroni C, Ceccato F, Rizzati S, Mantero F (2008) Concomitant therapies (glucocorticoids and sex hormones) in adult patients with growth hormone deficiency. J Endocrinol Invest 31(9 Suppl):61\u201365","journal-title":"J Endocrinol Invest"},{"key":"1940_CR38","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1007\/s11695-018-3359-9","volume":"28","author":"SR van Mil","year":"2018","unstructured":"van Mil SR, Vijgen GHEJ, van Huisstede A, Klop B, van de Geijn GM, Birnie E, Braunstahl GJ, Mannaerts GHH, Biter LU, Castro Cabezas M (2018) Discrepancies between BMI and classic cardiovascular risk factors. Obes Surg 28:3484\u20133491. https:\/\/doi.org\/10.1007\/s11695-018-3359-9","journal-title":"Obes Surg"},{"key":"1940_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A (2018) Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6:173\u2013185. https:\/\/doi.org\/10.1016\/S2213-8587(17)30398-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1940_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4158\/EP161428.OR","volume":"23","author":"A Al Nofal","year":"2017","unstructured":"Al Nofal A, Bancos I, Benkhadra K, Ospina NM, Javed A, Kapoor E, Muthusamy K, Brito JP, Turcu AF, Wang Z, Prokop L, Erickson DZ, Lteif AN, Natt N, Murad MH (2017) Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr Pract 23:17\u201331. https:\/\/doi.org\/10.4158\/EP161428.OR","journal-title":"Endocr Pract"},{"key":"1940_CR41","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1530\/EJE-13-0450","volume":"169","author":"A Grossman","year":"2013","unstructured":"Grossman A, Johannsson G, Quinkler M, Zelissen P (2013) Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 169:R165\u2013R175. https:\/\/doi.org\/10.1530\/EJE-13-0450","journal-title":"Eur J Endocrinol"},{"key":"1940_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2265.2011.04074.x","volume":"75","author":"LA Behan","year":"2011","unstructured":"Behan LA, Rogers B, Hannon MJ, O\u2019Kelly P, Tormey W, Smith D, Thompson CJ, Agha A (2011) Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol (Oxf) 75:505\u2013513. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04074.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1940_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/MED.0000000000000169","volume":"22","author":"I Crespo","year":"2015","unstructured":"Crespo I, Santos A, Webb SM (2015) Quality of life in patients with hypopituitarism. Curr Opin Endocrinol Diabetes Obes 22:306\u2013312. https:\/\/doi.org\/10.1097\/MED.0000000000000169","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01940-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T10:05:54Z","timestamp":1676628354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01940-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01940-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Prof. Emanuela Arvat and Silvia Grottoli are among the Members of the Editorial Board of the Journal of Endocrinological Investigation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave their written informed consent to participate in the study, which had been approved by the Ethical Committee of the University of Turin, in agreement with the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}